Watkin K L, Ewanowski S J
J Speech Hear Res. 1985 Jun;28(2):301-4. doi: 10.1044/jshr.2802.301.
The present investigation compared the effects of triamcinolone acetonide (Aristocort Aerosol) and beclomethasone dipropionate (Vanceril Inhaler) on the vocal functioning of 11 chronic asthmatics. Using conventional aero-acoustic techniques, subjects' vocal fundamental frequency, maximum phonation time, and oral air volume velocity were sampled at baseline (oral corticosteroid use) and at the end of the first and second year of aerosol triamcinolone acetonide use. At the end of the second year of aerosol triamcinolone acetonide use, all subjects discontinued use of this compound and began use of aerosol beclomethasone dipropionate. Subjects' vocal performance then was sampled after 1 year of aerosol beclomethasone dipropionate use. Results of this study suggest that aerosol triamcinolone acetonide reduced the vocal dysfunction observed during the baseline period. When aerosol beclomethasone dipropionate was used, however, subjects' vocal performance was similar to that observed during the baseline period (oral steroid use).
本研究比较了曲安奈德（曲安奈德气雾剂）和二丙酸倍氯米松（必可酮吸入剂）对11名慢性哮喘患者发声功能的影响。使用传统的空气声学技术，在基线期（口服皮质类固醇使用时）以及使用曲安奈德气雾剂的第一年和第二年末，对受试者的嗓音基频、最大发声时间和口腔气流量速度进行采样。在使用曲安奈德气雾剂的第二年末，所有受试者停止使用该化合物并开始使用二丙酸倍氯米松气雾剂。在使用二丙酸倍氯米松气雾剂1年后，对受试者的发声表现进行采样。本研究结果表明，曲安奈德气雾剂减轻了基线期观察到的发声功能障碍。然而，当使用二丙酸倍氯米松气雾剂时，受试者的发声表现与基线期（口服类固醇使用时）观察到的相似。
